Compounds > 2,6-dimethylphenylphthalimide
Page last updated: 2024-11-06

2,6-dimethylphenylphthalimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-dimethylphenylphthalimide: enhances alpha-tumor necrosis factor production; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73324
CHEMBL ID8916
SCHEMBL ID10491139
MeSH IDM0245153

Synonyms (22)

Synonym
OPREA1_422137 ,
20730-99-8
2-(2,6-dimethylphenyl)isoindoline-1,3-dione
n-(2,6-dimethylphenyl)phthalimide
MLS000107306
smr000111677
STK267942
2-(2,6-dimethylphenyl)-1h-isoindole-1,3(2h)-dione
AK-918/40178749
CHEMBL8916 ,
2-(2,6-dimethylphenyl)isoindole-1,3-dione
bdbm50066441
2-(2,6-dimethyl-phenyl)-isoindole-1,3-dione
AKOS003242716
HMS2500D23
1h-isoindole-1,3(2h)-dione, 2-(2,6-dimethylphenyl)-
2,6-dimethylphenylphthalimide
SCHEMBL10491139
DTXSID10174802
SR-01000214289-1
sr-01000214289
n-(2,6-dimethylphenyl)isoindoline-1,3-dione

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Anticonvulsant ED50s (effective doses in at least 50% of animals tested) of compounds in the MES test were determined in rats dosed orally and amounted to 52 (1), 135 (2), 284 (3), 231 (8), 131 (9), 25 (10), 369 (13), 354 (14), and 121 (PHT) micromol/kg, compound 5 presenting with an ED50 value higher than 650 micromol/kg."( Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
Lambert, D; Masereel, B; Poupaert, JH; Stables, JP; Vamecq, J, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID743255
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)0.00100.00032.177410.0000AID162144
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)398.00000.00010.444410.0000AID56226
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)0.00100.00101.453910.0000AID160735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID109361Anticonvulsant activity determined at 4 hours after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID109352Anticonvulsant activity determined at 30 minutes after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID168606Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 15 minutes by MES test. (+++ denotes activity in 50-75% of administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID125454Neurotoxicity by rotarod test after intraperitoneal administration at a concentration of 300 mg/kg after 30 minutes; Inactive2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID257637Inhibitory activity in HUVEC tube formation assay at 30 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID171974Anticonvulsant activity was measured in rats through seizures induced by maximal electroshock (MES) tests by oral administration of drug after 1 hour.2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID160735Inhibitory activity (RA2) against Prostaglandin G/H synthase 2 was calculated relative to aspirin2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Thalidomide and its analogues as cyclooxygenase inhibitors.
AID162144Inhibitory activity (RA1) against Prostaglandin G/H synthase 1 was calculated relative to aspirin2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Thalidomide and its analogues as cyclooxygenase inhibitors.
AID251887Cell growth-inhibitory activity toward human leukemia cell line HL60 at 3 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID56226Inhibitory activity against Dipeptidylpeptidase IV (DPP IV) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID126240Anticonvulsant activity in mice through seizures induced by maximal electroshock (MES) tests after ip administration at a concentration of 300 mg/kg after 4 hours; Inactive2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID211678Neurotoxicity determined at 30 minutes after the administration of compound by rotarod test.(- denotes activity at 300 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID126247Anticonvulsant activity in mice through seizures induced by scpentylenetetrazol (intraperitoneal administration at a concentration of 300 mg/kg after 4 hours; Inactive2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID126243Anticonvulsant activity in mice through seizures induced by sc pentylenetetrazole (intraperitoneal administration at a concentration of 300 mg/kg after 30 min; Inactive2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID171627Toxicity was determined in rats at a dose of 30 mg/kg after 4 hour. (- denotes no activity in administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID168753Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 2 hour by MES test. (+ denotes activity in 0-25% of administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID178278Anticonvulsant ED50 activity by MES test in rats dosed orally1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID1057533Antiproliferative activity against human PC3 cells assessed as growth inhibition at 30 uM by MTS assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.
AID38364Inhibitory activity against aminopeptidase N (APN) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID218272In vitro cytotoxicity against human embryonic lung fibroblast WI-38 cells.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID168762Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 4 hour by MES test. (+++ denotes activity in 50-75% of administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID257638Inhibitory activity in HUVEC tube formation assay at 10 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID172105Anticonvulsant activity was measured in rats through seizures induced by maximal electroshock (MES) tests by oral administration of drug after 4 hours.2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID191650Toxicity screening in rats dosed orally with the compound; No toxicity2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID168603Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 1 hour by MES test. (++ denotes activity in 25-50% of administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID251888Cell growth-inhibitory activity toward human leukemia cell line HL60 at 6 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID251886Cell growth-inhibitory activity toward human leukemia cell line HL60 at 10 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID125458Neurotoxicity determined by rotarod test after intraperitoneal administration at a concentration of 300 mg/kg after 4 hours; Inactive2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID109358Anticonvulsant activity determined at 4 hours after the administration of compound using MES test.(- denotes activity at 300 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID81272Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 50 nM okadaic acid (OA), at 30 uMolar.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID172102Anticonvulsant activity was measured in rats through seizures induced by maximal electroshock (MES) tests by oral administration of drug after 2 hours.2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID211683Neurotoxicity determined at 4 hours after the administration of compound by rotarod test(- denotes activity at 300 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID109347Anticonvulsant activity determined at 30 minutes after the administration of compound using MES test.(++= signify activity at 100 mg/kg)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID219416Cytotoxicity in human embryonic lung flbroblast Wl-38 cells using WST-1 viability assay1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID81275Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 10 nM 12-O-tetradecanoylphorbol 13-acetate (TPA) at 30 uMolar.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID168757Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 30 minutes by MES test. (+++ denotes activity in 50-75% of administered animals).1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID172103Anticonvulsant activity was measured in rats through seizures induced by maximal electroshock (MES) tests by oral administration of drug after 30 minutes.2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID126237Anticonvulsant activity in mice through seizures induced by maximal electroshock (MES) tests after ip administration at a concentration of 100 mg/kg after 30 min; active2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
AID205272Apparent IC50 value by [3H]batrachotoxinin-A-20-alpha-benzoate-binding test performed in rat brain synaptosomes1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide.
AID38377Inhibitory activity against aminopeptidase N assayed by the L-Ala-MCA method.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.
AID257636Inhibitory activity in HUVEC tube formation assay at 100 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID172100Anticonvulsant activity was measured in rats through seizures induced by maximal electroshock (MES) tests by oral administration of drug after 15 minutes.2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (33.33)18.2507
2000's5 (33.33)29.6817
2010's4 (26.67)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.53 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenytoin
[no description available]		2.420imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		2.9340phthalimides;
piperidones
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.0210alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
ameltolide
ameltolide: structure given in first source; RN given refers to parent cpd		1.9910benzamides
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9810acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
n-phenylphthalimide
N-phenylphthalimide: structure given in first source		2.9340
ubenimex
ubenimex: growth inhibitor		2.420
4-amino-n-(2,6-dimethylphenyl)phthalimide
4-amino-N-(2,6-dimethylphenyl)phthalimide: a potent anticonvulsant against maximal electroshock-induced seizures; structure given in first source		2.6930
pomalidomide
3-aminophthalimidoglutarimide: structure in first source		2.0210aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lenalidomide
[no description available]		2.0210aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
actinonin
actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure		1.9910
2-(2,6-diisopropylphenyl)-5-amino-1h-isoindole-1,3-dione
2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione: an antineoplastic agent; structure in first source		3.2660
5-hydroxythalidomide
5-hydroxythalidomide: do not confuse with 5'-hydroxythalidomide		2.4320phthalimides
n-(4-amino-2-chlorophenyl)phthalimide
N-(4-amino-2-chlorophenyl)phthalimide: has anticonvulsant activity; structure in first source		210
pp-33
[no description available]		3.2660
2-(2,6-diisopropylphenyl)-5-hydroxy-1h-isoindole-1,3-dione
2-(2,6-diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione: structure in first source		3.2660
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.420
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.420
Deficiency, Magnesium
[description not available]		0210
Magnesium Deficiency
A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)		0210
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Leucocythaemia
[description not available]		01.9810
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9810